m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02422)
Name
TT-301
Synonyms
Minozac; MW01-9-034WH; Anti-neuroinflammatories (Alzheimer's disease), NeuroMedix/Transition Therapeutics
    Click to Show/Hide
Status
Phase 1
Structure
Formula
C23H21N7
InChI
1S/C23H21N7/c1-2-5-19(6-3-1)21-17-20(18-7-11-24-12-8-18)22(28-27-21)29-13-15-30(16-14-29)23-25-9-4-10-26-23/h1-12,17H,13-16H2
InChIKey
ZPJGUEPHFXPAQF-UHFFFAOYSA-N
PubChem CID
54576073
TTD Drug ID
D00EHX
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Interleukin-1 beta (IL1B)
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Interleukin-1 beta (IL1B) is a therapeutic target for TT-301. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of TT-301 through regulating the expression of Interleukin-1 beta (IL1B). [1], [2]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Interleukin-1 beta (IL1B) is a therapeutic target for TT-301. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of TT-301 through regulating the expression of Interleukin-1 beta (IL1B). [2], [3]
YTH domain-containing family protein 3 (YTHDF3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Interleukin-1 beta (IL1B) is a therapeutic target for TT-301. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of TT-301 through regulating the expression of Interleukin-1 beta (IL1B). [1], [2]
References
Ref 1 N6-methyladenosine reader YTH N6-methyladenosine RNA binding protein 3 or insulin like growth factor 2 mRNA binding protein 2 knockdown protects human bronchial epithelial cells from hypoxia/reoxygenation injury by inactivating p38 MAPK, AKT, ERK1/2, and NF-KappaB pathways. Bioengineered. 2022 May;13(5):11973-11986. doi: 10.1080/21655979.2021.1999550.
Ref 2 Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1Beta antibody, in patients with type 2 diabetes. Diabetes Care. 2013 Aug;36(8):2239-46. doi: 10.2337/dc12-1835. Epub 2013 Mar 20.
Ref 3 RNA m6A reader YTHDF1 facilitates inflammation via enhancing NLRP3 translation. Biochem Biophys Res Commun. 2022 Aug 6;616:76-81. doi: 10.1016/j.bbrc.2022.05.076. Epub 2022 May 24.